Article
What CMS published
The advance notice of proposed rulemaking, published in the Federal Register on Jan. 29, does not set policy yet. It outlines a voluntary “Secure American Medical Supplies” designation for hospitals that attest on their cost reports to buying domestic products. Designated hospitals would receive a separate Medicare payment for the added cost of those items, covering Medicare’s inpatient share. CMS raises the option of making the payment outside budget neutrality, and suggests paying it as a lump sum at cost report settlement or through interim payments reconciled later.
The scope covers protective equipment such as masks, respirators, gloves, gowns and face shields, plus the 86 essential medicines on a 2022 federal supply chain list. For drugs, CMS proposes a domestic definition requiring more than half of the active ingredient and the entire finished dose to be made in the US. It also asks whether to add items such as syringes, needles and catheters, and whether to extend the approach to outpatient payment.
The quality reporting piece
Alongside the payment, CMS floats a structural measure in the inpatient quality reporting program. Hospitals would attest whether they meet minimum domestic purchasing shares for PPE and essential medicines, with a phased path from at least 25% to 50% and eventually 75%. No threshold is set.
Why the economics need careful review
The cost gap is real. CMS cites federal price reviews showing domestic nitrile gloves cost roughly 1.5 to 3 times imported gloves, and domestic active ingredients about 12 times as much on average. The agency’s own illustration for a hospital with 10,000 Medicare patient days puts the N95 premium at about $10,000 a year. Uptake of a similar existing adjustment has been thin: fewer than 100 hospitals reported the N95 payment for fiscal 2024.
Because payment would cover only Medicare’s share, hospitals would absorb the premium on purchases tied to other payers. Supply availability is another constraint, since domestic production of many generic drugs and some PPE categories remains limited.
What to do before March 30
- Map current sourcing. Estimate what share of your PPE and listed essential medicines is already domestic, using distributor and group purchasing data.
- Model the net cost. Compare the premium on all purchases with Medicare’s share of reimbursement under the payment options described.
- Weigh resilience value. Shortages during the pandemic and recent drug supply disruptions carry costs that do not appear in unit prices.
- Comment on the details. Thresholds, product definitions and reporting burden are still open, and hospital input can shape them.
Archive entry for Jan 31, 2026, added Nov. 11, 2026.